Biotechnology: Capital vs. Biological Truth

The article analyzes the fundamental tension between biological time, which is slow and unpredictable, and capital time, which strives for quick quarterly results. The author warns that investor pressure for certainty and attractive narratives can lead to avoiding breakthrough but risky projects in favor of safer solutions. In biotechnology, haste carries a particular moral weight, as research errors directly threaten patient health. The text emphasizes that treating negative results as a communication failure rather than valuable scientific information leads to dangerous selective data perception. True innovation requires time and the acceptance of uncertainty; without these, science becomes merely theater for shareholders.